Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression data from IMR90 Control, IMR90 HRAS-G12V, IMR90 HRAS-G12V+shDOT1L, IMR90 DOT1L Overexpression

ABSTRACT: Gene expression data from IMR90 Control, IMR90 HRAS-G12V, IMR90 HRAS-G12V+shDOT1L, IMR90 DOT1L Overexpression

PROVIDER: PRJNA658579 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12492510_1.fastq.gz	Fastqsanger.gz
	SRR12492510_2.fastq.gz	Fastqsanger.gz
	SRR12492511_1.fastq.gz	Fastqsanger.gz
	SRR12492511_2.fastq.gz	Fastqsanger.gz
	SRR12492512_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Gene expression data from IMR90 Control, IMR90 HRAS-G12V, IMR90 HRAS-G12V+shDOT1L, IMR90 DOT1L Overexpression

Project description:Gene expression data from IMR90 Control, IMR90 HRAS-G12V, IMR90 HRAS-G12V+shDOT1L, IMR90 DOT1L Overexpression

| PRJNA658579 | ENA

Gene expression data from IMR90 Control, IMR90 HRAS-G12V, IMR90 HRAS-G12V+shDOT1L, IMR90 DOT1L Overexpression

Project description:Oncogene-induced senescent cells display a robust change in their epigenome and have increased transcription and secretion of numerous pro-inflammatory cytokines and chemokines termed the senescence-associated secretory phenotype (SASP). Therefore, understanding how and if the epigenome is involved in regulating the transcription of the SASP is critical to understanding how to restrain the harmful effects of the SASP. The active histone marks H3K79me2 and H3K79me3 and their methyltransferase DOT1L are increased during oncogene-induced senescence. Whether H3K79 methylation and DOT1L expression are involved in the transcriptional regulation of the SASP is unknown.

2020-08-21 | GSE156648 | GEO

ChIP-Seq data from IMR90 Control and IMR90 HRAS-G12V using an H3K79me3 antibody

Project description:ChIP-Seq data from IMR90 Control and IMR90 HRAS-G12V using an H3K79me3 antibody

| PRJNA658469 | ENA

ChIP-Seq data from IMR90 Control and IMR90 HRAS-G12V using an H3K79me3 antibody

2020-08-21 | GSE156591 | GEO

Transcriptome analysis of skeletal muscle tissue from Hras G12V mutant mice

Project description:Transcriptome analysis of skeletal muscle tissue from Hras G12V mutant mice

| PRJNA777595 | ENA

Transcription profiling by array of human MCF10A cells reveal changes upon expression of activated versions of MEK1 and HRAS

Project description:MCF10A cells were then transfected with MEK1(S217S221), HRAS(G12V), and null control vectors; Cells were lysed 24 hours post-transfection with collection of total RNA and protein Experiment Overall Design: Overexpression of Oncogenic protein was confirmed via Western blot

2009-01-17 | E-GEOD-12764 | biostudies-arrayexpress

Functional robustness of spermatogonial stem cells after induction of hyperactive Hras

Project description:We report on gene expression in stem cell-enriched, undifferentiated spermatogonia isolated from the adult mouse testis, in which one group are wild type and the other group contain a heterozygous Hras G12V mutation.

2019-04-18 | GSE129493 | GEO

Gene expression changes upon expression of activated versions of MEK1 and HRAS in MCF10A cells

Project description:MCF10A cells were then transfected with MEK1(S217S221), HRAS(G12V), and null control vectors Cells were lysed 24 hours post-transfection with collection of total RNA and protein Keywords: Oncogene inducation of gene expression changes

2009-01-12 | GSE12764 | GEO

Normal mouse skin lacking Hras

Project description:Oncogenic activating mutations in Ras genes are among the most common drivers of human disease. Treating mouse skin with the chemical carcinogen DMBA induces a characteristic mutation in Hras at codon 61. To understand how skin responds to a constitutive lack of Hras, we generated a cohort of Hras knockout mice.

2015-03-01 | GSE60769 | GEO

RNA-seq analysis of murine KMT2A-MLLT3 with DOT1L overexpressed

Project description:We transduced two individual murine KMT2A-MLLT3 AML samples with DOT1L and three days after sorting for DOT1L+ cells collected for RNA-seq MLL-rearranged leukemias have been previously shown to be dependent on the presence of histone 3 lysine 79 (H3K79) dimethylation on the genomic targets of the fusion, and an inhibitor of the H3K79 methyltransferase DOT1L is in clinical trials for MLL-rearranged leukemia. In order to ask what biologic effects overexpression of DOT1L would have on the H3K79me2 ChIP-Seq profiles and MLL-fusion target gene expression, murine leukemias generated by transplanting MSCV-MLL-AF9-GFP transduced lin- cKit+ Sca1+ bone marrow cells were subjected to overexpression of DOT1L. Cells were sorted into low (low level of DOT1L overexpression), high (high level of DOT1L overexpression) and bulk (entire population) samples, and subjected to H3K79me2 ChIP-Seq (using a drosophila spike in for normalization) and RNA-Seq analysis 3 days after transduction.

2019-07-10 | GSE134035 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data